← 產業報告目錄
Ischemic Heart Disease (IHD) Drugs Market Size, Share & Trends Analysis Report, By Disease class (angina pectoris, myocardial infarction), By Drug Class (Anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, ACE inhibitors, arbs, vasodilators, antithrombotic agents), By Region, Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-08頁數 180報告編號 INSIGHTACE-e3ae8d5324
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The worldwide Ischemic Heart Disease (IHD) Drugs Market stood at USD 6.07 Bn in 2023, and is expected to reach USD 8.46 Bn by 2031, recording a CAGR of 4.4% from 2024 through 2031.
Ischemic Heart Disease (IHD) Drugs encompasses those that treat situations where the heart does not receive enough blood, most often because the coronary arteries are too small or too clogged. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Growth is bolstered by a convergence of factors: rising awareness among end users, continuous product innovation, and the surging emphasis on efficiency and sustainability within the healthcare sector.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region expected to deliver the strongest growth trajectory through the forecast period, bolstered by demographic shifts and policy support.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Ischemic Heart Disease (IHD) Drugs Market Snapshot
Chapter 4. Global Ischemic Heart Disease (IHD) Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Disease Estimates & Trend Analysis
5.1. by Disease & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Disease:
5.2.1. Angina Pectoris
5.2.2. Myocardial Infarction
Chapter 6. Market Segmentation 2: by Drug Class Estimates & Trend Analysis
6.1. by Drug Class & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Drug Class:
6.2.1. Anti-Dyslipidemic Drugs
6.2.2. Calcium Channel Blockers
6.2.3. Beta-Blockers
6.2.4. ACE Inhibitors
6.2.5. ARBs
6.2.6. Vasodilators
6.2.7. Antithrombotic Agents
Chapter 7. Ischemic Heart Disease (IHD) Drugs Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2019-2031
7.1.2. North America Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2019-2031
7.1.3. North America Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.2. Europe
7.2.1. Europe Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2019-2031
7.2.2. Europe Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2019-2031
7.2.3. Europe Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2019-2031
7.3.2. Asia Pacific Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2019-2031
7.3.3. Asia Pacific Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.4. Latin America
7.4.1. Latin America Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2019-2031
7.4.2. Latin America Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2019-2031
7.4.3. Latin America Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2019-2031
7.5.2. Middle East & Africa Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2019-2031
7.5.3. Middle East & Africa Ischemic Heart Disease (IHD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Bayer AG
8.2.2. Eli Lilly and Company
8.2.3. Novartis International AG
8.2.4. Pfizer, Inc.
8.2.5. Sanofi S.A.
8.2.6. Actelion Pharmaceuticals Ltd.
8.2.7. Baxter International Inc.
8.2.8. Boehringer Ingelheim International GmbH
8.2.9. Bristol-Myers Squibb Company
8.2.10. Amgen Inc.
8.2.11. F. Hoffmann-La Roche AG
8.2.12. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們